Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina

Vaccine

Volumn 28, Issue 11, 2010, Pages 2302-2310

  Giglio, Norberto D ^a   Cane, Alejandro D ^b,c   Micone, Paula ^b   Gentile, Angela ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c Wyeth SA ^*  (Argentina)

Author keywords

Cost effectiveness; Heptavalent Pneumococcal conjugate vaccine

Indexed keywords

DIPHTHERIA TOXOID CRM197; PNEUMOCOCCUS VACCINE;

ARGENTINA; ARTICLE; BACTEREMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; HOSPITALIZATION; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; OTITIS MEDIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROBABILITY; STREPTOCOCCUS PNEUMONIA; VACCINATION;

ARGENTINA; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INFANT; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 77049106261     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.070     Document Type: Article

References (54)

1. Ruvinsky R. Epidemiology of invasive infections by Streptococcus pneumoniae. Rev Hosp Ninos Buenos Aires 47 (2005) 222-232
2. Di Fabio J.l., Hortal M., Iraola I., and Camou T. Surveillance and prevention of pneumococcias in Latin America. Multidisciplinary advances for control of S. pneumoniae. PAHO (2004) 1-14
3. Marchetti M., and Colombo G.L. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 23 37 (2005) 4565-4576
4. Wisløff T., Abrahamsen T.G., Bergsaker M.A., Løvoll Ø., Møller P., Pedersen M.K., et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24 29-30 (2006) 5690-5699
5. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 4 (1993) 322-338
6. Naimark D., Krahn M.D., Naglie G., Redelmeier D.A., and Detsky A.S. Primer on medical decision analysis: Part 5-working with Markov processes. Med Decis Making 17 2 (1997) 152-159
7. Yearbook. National Institute of Statistics and Census Argentina; 2006.
8. Naglie G., Krahn M.D., Naimark D., Redelmeier D.A., and Detsky A.S. Primer on medical decision analysis: Part 3-estimating probabilities and utilities. Med Decis Making 17 2 (1997) 136-141
9. Tregnaghi M., Ceballos A., Rüttimann R., Ussher J., Tregnaghi P., Peeters P., et al. Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr Infect Dis J 25 4 (2006) 370-372
10. Tregnaghi M., Ceballos A., Ruttimann R., Peeters P., Tregnaghi J.P., Ussher J., et al. An active epidemiologic surveillance of neumococcal disease in the outpatient and hospitalization settings. Arch Argent Pediatr 104 1 (2006) 3-9
11. Garcia S, Levine O, Cherian T, Gabastou J, Andrus J. Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction. Rev. Panam. Salud Pública = Pan am. j. public health mayo 2006;19(5):340-48.
12. Centers for Disease Control Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 576 (2008) 144-148
13. Baraff L.J., Lee S.I., and Schriger D.L. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 12 5 (1993) 389-394
14. Teele D.W., Klein J.O., and Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 160 July (1) (1989) 83-94
15. Sinha A., Constenla D., Valencia J.E., O'Loughlin R., Gomez E., de la Hoz F., et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica 24 5 (2008) 304-313
16. Constenla D.O. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publica 24 (2008) 101-112
17. Lagos R., Muñoz A., Valenzuela M.T., Heitmann I., and Levine M.M. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr Infect Dis J 21 12 (2002) 1115-1123
18. Bakir J., Turco M., Umido V., Man C., Romanin V., Procopio A., et al. Epidemiology of bacterial meningitis in a pediatric hospital. Rev Hosp Niños Buenos Aires 47 214 (2005) 217-221
19. Abate H., Apra E., Barros F., Cibau C., and Rosaenz A. Morbidity and mortality of no neonatal childhood bacterial meningitis. Arch Argent Pediatr 97 5 (1999) 300-305
20. National Immunization Schedule of Argetina. Argentina Pediatrics Society. www.sap.org.ar [access 16 April, 2009].
21. Shepard C.W., Ortega-Sanchez I.R., Scott R.D., Rosenstein N.E., and ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115 5 (2005) 1220-1232
22. Ruvinsky R., Gentile A., Regueira M., and Corso A. Epidemiology of invasive Streptococcus pneumoniae infections. Epidemiological study and importance of surveillance system. Arch Argent Pediatr 100 1 (2002) 31-43
23. Gabastou J.M. Informe regional de SIREVA II, 2008 (2009), Organización Panamericana de la Salud
24. Hausdorff W.P., Yothers G., Dagan R., Kilpi T., Pelton S.I., Cohen R., et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 21 11 (2002 Nov) 1008-1016
25. Lamy P., Nolte F., and Gentile A. Critical analysis of vaccination coverage in the country. Rev Hosp Niños Buenos Aires 47 214 (2005) 201-204
26. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
27. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002) 810-815
28. Zhou F., Kyaw M.H., Shefer A., Winston C.A., and Nuorti J.P. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 161 12 (2007) 1162-1168
29. Bos J.M., Rümke H., Welte R., and Postma M.J. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 25 10 (2003) 2614-2630
30. Klein J. External Otitis, Media Otitis and Mastoiditis. In: Geral, Mandell, Bennett Dolin (eds.), Mandell, Douglas and Bennet's Principles and Practice of Infectious Diseases IV Edition, Vol I, pp. 579-590; 1995.
31. Gentile A., Bakir J., Moar A., Burna V., Bustamante G., and Mistchenko A. Epidemiological profile of acute lower respiratory infections in a pediatric hospital. Arch Argent Pediatr 94 1 (1996) 2-9
32. Kairos L.L. Manual farmaceutico (2005), E.C.S.A. ISNN 0327-6341
33. Maceira D. Horizontal and vertical dimensions in the social health insurance in Latin America and the Caribbean. 2001. www.danielmaceira.com.ar/produccion_academica_0001.htm [access 22 August 2009].
34. IDESA. Number 249-August 31; 2008. Available http://www.idesa.org [access 22 August, 2009].
35. IDESA. Number 216-January 20; 2008. Available: http://www.idesa.org [access 22 August, 2009].
36. IDESA. Number 217-January 27, 2008. Available http://www.idesa.org [access 22August, 2009].
37. IDESA. Number 118-March 5, 2006. Available http://www.idesa.org [access 22 August 2009].
38. Hutton J.L., and Cooke T. Pharoah PO Life expectancy in children with cerebral palsy. BMJ 309 August (6952) (1994) 431-435
39. Prieto L., Sacristán J.A., Pinto J.L., Badia X., Antoñanzas F., and del Llano J. Analysis of costs and results of the economic assessment of health interventions. Med Clin (Barc) 122 11 (2004) 423-429
40. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 April (9568) (2007) 1179-1186
41. Centers for Disease Control Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54 September (36) (2005) 893-897
42. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., and Craig A.S. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360 January (3) (2009) 244-256
43. Valenzuela M.T., Jacobs R.J., Arteaga O., Navarrete M.S., Meyerhoff A.S., and Innis B.L. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 23 July (32) (2005) 4110-4119
44. TreeAge Software Inc., Williamstown, MA.
45. Zhou F., Shefer A., Kong Y., and Nuorti J.P. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121 February (2) (2008) 253-260
46. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children.
47. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., and Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22 January (1) (2003) 10-16
48. Costeffectiveness. thresholds www.who.int/choice/cost/cer_thresholds/en/index.html [access 4 de abril 2009].
49. WHO Argentina www.who.int/countries/arg/en [access 4 de abril 2009].
50. Ray T. In: Siber, Klugman, and Makela (Eds). Pharmacoeconomics of pneumococcal conjugate vaccines-pneumococcal vaccines (2008), ASM Press WDC
51. Lieu T., Ray G.T., Black S., Shinefield H., Butler J., and Miller M. Cost-effectiveness of pneumococcal vaccine. JAMA 284 4 (2000) 440-441
52. Moore D. Modeling the cost and effects of universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can Commun Dis Rep 29 (2003) 97-104
53. Salo H., Sintonen H., Nuorti J.P., Linna M., Nohynek H., Verho J., et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis 37 11-12 (2005) 821-832
54. Ess S.M., Schaad U.B., Gervaix A., Pinösch S., and Szucs T.D. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 21 23 (2003) 3273-3281